1ST Gulf

Advisory Board on

Thyroid Eye Disease

06:00 pm - 09:30 PM UAE time

Venue: Emirates Jumeirah Towers - Dubai

Dear Doctor,

Kindly take few minutes to answer

this pre-meeting survey.

Please enter your full name

TED initial diagnosis, epidemiology and multi-disciplinary involvement:

  1. Do you co-manage patients with TED with another specialist/physician?
    Please Answer this question
    Mention the specialist/physician types do you co-manage with
    Please Answer this question
  2. What percentage of your TED patients come from referral vs direct visit?
    Please Answer this question
  3. What percentage of your practice is dedicated to diagnosing and managing patients with TED?
    Please Answer this question
  4. Approximately, what is the yearly incidence of TED cases in your center?
    Please Answer this question

How do you describe your Thyroid Eye Disease treatment modality?

(Please indicate the dose, frequency, and route of administration for each of the 1st and 2nd line treatments you currently use.)

Please Answer this question

For the next 3 questions, please refer to Teprotumumab clinical data in the pre-read material provided:

  1. From the data provided, what do you see as THREE strengths for Teprotumumab?
    Please Answer this question
  2. From the data provided, what do you see as THREE weaknesses for Teprotumumab?
    Please Answer this question
  3. What data, if any, from the Phase 3 OPTIC/OPTIC-X trial would you like more information/clarification on?
    Please Answer this question

Thank You.

Your response was submitted successfully.

SC-GL-Tep-00019